Table of Contents
Hepatitis Research and Treatment
Volume 2014 (2014), Article ID 631481, 7 pages
http://dx.doi.org/10.1155/2014/631481
Research Article

Portraying Persons Who Inject Drugs Recently Infected with Hepatitis C Accessing Antiviral Treatment: A Cluster Analysis

1CRCHUM (Centre de Recherche du Centre Hospitalier de l’Université de Montréal), Tour Saint-Antoine 850, Rue St-Denis, Montréal, QC, Canada H2X 0A9
2Département de Médecine Familiale, Faculté de Médecine, Université de Montréal, Pavillon Roger-Gaudry, Bureau S-711, 2900 boul. Édouard-Montpetit, Montréal, QC, Canada H3T 1J4
3Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Campus Longueuil 1111, Rue St-Charles Ouest, Bureau 500, Longueuil, QC, Canada J4K 5G4
4Family Medicine Department, McGill University, 5858 Chemin de la Côte des Neiges, 3e Étage, Montréal, QC, Canada H3S 1Z1

Received 26 May 2014; Revised 18 September 2014; Accepted 18 September 2014; Published 1 October 2014

Academic Editor: Alessandro Antonelli

Copyright © 2014 Jean-Marie Bamvita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. W. Shepard, L. Finelli, and M. J. Alter, “Global epidemiology of hepatitis C virus infection,” The Lancet Infectious Diseases, vol. 5, no. 9, pp. 558–567, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Ueno, J. D. Sollano, and G. C. Farrell, “Prevention of hepatocellular carcinoma complicating chronic hepatitis C,” Journal of Gastroenterology and Hepatology, vol. 24, no. 4, pp. 531–536, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. W. A. Zule and D. P. Desmond, “Factors predicting entry of injecting drug users into substance abuse treatment,” The American Journal of Drug and Alcohol Abuse, vol. 26, no. 2, pp. 247–261, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. J. G. McHutchison, J. E. Ware Jr., M. S. Bayliss et al., “The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity,” Journal of Hepatology, vol. 34, no. 1, pp. 140–147, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. N. K. Martin, P. Vickerman, A. Miners et al., “Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations,” Hepatology, vol. 55, no. 1, pp. 49–57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. N. K. Martin, P. Vickerman, J. Grebely et al., “Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals,” Hepatology, vol. 58, no. 5, pp. 1598–1609, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. H. Mehta, B. L. Genberg, J. Astemborski et al., “Limited uptake of hepatitis C treatment among injection drug users,” Journal of Community Health, vol. 33, no. 3, pp. 126–133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Alavi, J. D. Raffa, G. D. Deans et al., “Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents,” Liver International, vol. 34, no. 8, pp. 1198–1206, 2014. View at Publisher · View at Google Scholar
  9. R. M. Andersen, “Revisiting the behavioral model and access to medical care: does it matter?” Journal of Health and Social Behavior, vol. 36, no. 1, pp. 1–10, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. S. A. Strathdee, M. Latka, J. Campbell et al., “Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users,” Clinical Infectious Diseases, vol. 40, supplement 5, pp. S304–S312, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. D. A. Luke, “Getting the big picture in community science: methods that capture context,” The American Journal of Community Psychology, vol. 35, no. 3-4, pp. 185–200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Bruneau, É. Roy, N. Arruda, G. Zang, and D. Jutras-Aswad, “The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users,” Addiction, vol. 107, no. 7, pp. 1318–1327, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. J. Coons, S. Rao, D. L. Keininger, and R. D. Hays, “A comparative review of generic quality-of-life instruments,” PharmacoEconomics, vol. 17, no. 1, pp. 13–35, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Bruneau, F. Lamothe, J. Soto et al., “Sex-specific determinants of HIV infection among injection drug users in Montreal,” CMAJ, vol. 164, no. 6, pp. 767–773, 2001. View at Google Scholar · View at Scopus
  15. M. J. Norusis, “Cluster Analysis,” Chapter 16 in IBM SPSS Statistics 19 Guide to Data Analysis, 2011, http://www.norusis.com/pdf/SPC_v13.pdf.
  16. IBM SPSS Statistics, “Analyse TwoStep Cluster,” 2011, http://www-01.ibm.com/support/knowledgecenter/SSLVMB_20.0.0/com.ibm.spss.statistics.help/idh_twostep_main.htm.
  17. M. S. Aldenderfer and R. K. Blasfield, Chapter 23: Cluster Analysis, Sage, 2014, http://www.uk.sagepub.com/burns/website%20material/Chapter%2023%20-%20Cluster%20Analysis.pdf.
  18. J. Grebely, J. D. Raffa, C. Lai et al., “Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents,” Journal of Viral Hepatitis, vol. 16, no. 5, pp. 352–358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. Hilsden, G. Macphail, J. Grebely, B. Conway, and S. S. Lee, “Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial,” Clinical Infectious Diseases, vol. 57, supplement 2, pp. S90–S96, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. C. E. McGowan and M. W. Fried, “Barriers to hepatitis C treatment,” Liver International, vol. 32, no. 1, pp. 151–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Digiusto and C. Treloar, “Equity of access to treatment, and barriers to treatment for illicit drug use in Australia,” Addiction, vol. 102, no. 6, pp. 958–969, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Treloar, P. Hull, G. J. Dore, and J. Grebely, “Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs,” Drug and Alcohol Review, vol. 31, no. 7, pp. 918–924, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Moirand, M. Bilodeau, S. Brissette, and J. Bruneau, “Determinants of antiviral treatment initiation in a hepatitis C-infected population benefiting from universal health care coverage,” Canadian Journal of Gastroenterology, vol. 21, no. 6, pp. 355–361, 2007. View at Google Scholar · View at Scopus
  24. S.-M. Alavian, A. Mirahmadizadeh, M. Javanbakht et al., “Effectiveness of methadone maintenance treatment in prevention of hepatitis C virus transmission among injecting drug users,” Hepatitis Monthly, vol. 13, no. 8, Article ID e12411, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Alavi, J. Grebely, M. Micallef et al., “Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study,” Clinical Infectious Diseases, vol. 57, supplement 2, pp. S62–S69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. J. D. Farley, V. K. Wong, H. V. Chung et al., “Treatment of chronic hepatitis C in Canadian prison inmates,” Canadian Journal of Gastroenterology, vol. 19, no. 3, pp. 153–156, 2005. View at Google Scholar · View at Scopus
  27. G. Gazdag, G. Horváth, O. Szabó, and G. S. Ungvari, “Barriers to antiviral treatment in hepatitis C infected intravenous drug users,” Neuropsychopharmacologia Hungarica, vol. 12, no. 4, pp. 459–462, 2010. View at Google Scholar · View at Scopus
  28. S. Manolakopoulos, M. J. Deutsch, O. Anagnostou et al., “Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C,” Liver International, vol. 30, no. 10, pp. 1454–1460, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Morrill, M. Shrestha, and R. W. Grant, “Barriers to the treatment of hepatitis C: patient, provider, and system factors,” Journal of General Internal Medicine, vol. 20, no. 8, pp. 754–758, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Roy, P. Leclerc, C. Morissette et al., “Prevalence and temporal trends of crack injection among injection drug users in eastern central Canada,” Drug and Alcohol Dependence, vol. 133, no. 1, pp. 275–278, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. United Nations Office on Drugs and Crime (UNODC), “Recent statistics and trend analysis of illicit drug markets,” 2012, http://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_Chapter1.pdf .
  32. J. de Irala, C. Bigelow, J. McCusker, R. Hindin, and L. Zheng, “Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population,” American Journal of Epidemiology, vol. 143, no. 7, pp. 725–732, 1996. View at Publisher · View at Google Scholar · View at Scopus